The tonic-clonic seizures treatment market was valued at USD 34.93 billion in 2023. The market is expected to grow at a CAGR of 6% during the period 2024-2032, reaching USD 55.84 billion by 2032. This ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) ...

GlaxoSmithKline’s antiseizure drug, Lamictal® (lamotrigine), was approved for a new epilepsy indication—one of the most serious forms of epilepsy, primary generalized tonic-clonic (PGTC) seizures.

Epilepsy is when the brain has an electrical misfire that causes multiple seizures. And depending on where the misfire takes place, the seizure will have different effects, such as freezing you or ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...

CLEVELAND — November marks National Epilepsy Awareness Month, drawing attention to a neurological condition that affects almost 3 million adults and nearly half a million children across the United ...

November is Epilepsy Awareness Month. Many people may already be aware of the condition from its prevalence in medical dramas, but that portrayal is often exaggerated and does not fully encapsulate ...